Pancreatic cancer

The article highlights ongoing developments in biotech, including discussions on Biogen’s tau therapy for Alzheimer’s at a London meeting, research on daraxonrasib for pancreatic cancer, and U.S. regulatory updates such as HHS guidance on tapering SSRIs and FDA approval of Sanofi’s wearable injector for a myeloma drug.

Researchers at a pancreatic cancer conference in London highlighted a new drug showing milestone clinical trial results, compared to checkpoint inhibitors in cancer treatment. The drug's progress has generated excitement among experts, though challenges remain ahead.

Memorial Regional Hospital in Hollywood is using an experimental drug, Daraxonrasib, to treat pancreatic cancer patients. Russell Reed, a Stage 2B pancreatic cancer patient, and his wife Marnie are advocating for access to the drug, which has shown extended survival times in trials compared to chemotherapy. Dr. Jesus Fabregas from the Memorial Cancer Institute highlights the drug's potential to improve quality of life by targeting a protein linked to cancer growth.

Chinese biotech firms are developing RAS-targeted cancer therapies that challenge U.S. companies like Revolution Medicines, whose drug improved survival for pancreatic cancer patients. Analysts note Chinese rivals are undervalued despite rapid progress in this competitive field.

The author quit their job to travel with their father, who was later diagnosed with pancreatic cancer and died 10 days after their trip began. A year later, the author is returning to work after grieving and managing their father's estate.

A study suggests that a specific duration of daily light exposure may reduce the risk of pancreatic cancer by 40%.

The author underwent a $12,000 longevity test at Human Longevity in Silicon Valley to assess cancer and other health risks after their father died of pancreatic cancer. The results showed a 99% chance of being cancer-free but revealed elevated risks for neurological conditions. The tests included genomic sequencing, blood work, and MRI scans.

A new pancreatic cancer drug program, Daraxonrasib, which is not fully FDA-approved, may help rural patients access treatment closer to home. Brad Dugai from Mathews County is one of the patients benefiting from this program.

An experimental drug is showing promise for pancreatic cancer patients, even in advanced stages. Doctors report that the treatment is providing hope for those with advanced pancreatic cancer.

A single pint of beer consumed daily is associated with a significantly increased risk of pancreatic cancer diagnosis. The study highlights the potential health risks linked to regular beer consumption.

A UCLA-led study found that pancreatic cancer patients taking daraxonrasib lived an average of 13.2 months, compared to 6.6-6.7 months with chemotherapy alone. The FDA granted early access to the drug for patients who failed standard treatments, as reported at the ASCO meeting in Chicago.

Patrick Soon-Shiong's claims about transforming pancreatic cancer treatment with novel immunotherapies are criticized for lacking clinical evidence, with a gap between his promises and actual FDA-approved outcomes. The article highlights his history in treating pancreatic cancer and the 'Bioshield' mission, while noting financial self-interest and regulatory scrutiny.

A study found that adding vitamin D supplementation to chemotherapy for pancreatic cancer was safe and reduced tumor-protective tissue density while increasing immune T-cells. The results suggest potential for improving treatment outcomes in hard-to-treat pancreatic cancers.

A clinical trial showed improved outcomes for pancreatic cancer patients using a combination of Tango Therapeutics' PRMT5 inhibitor and Revolution Medicines' pan-RAS inhibitor. The article speculates on potential biotech mergers and acquisitions involving companies like Revolution Medicines, Tango Therapeutics, and Bristol Myers Squibb.

Tango Therapeutics' stock surged after a combination of vopimetostat and Revolution Medicines' daraxonrasib showed a 92% response rate in patients with advanced pancreatic cancer.

The newly developed treatment daraxonrasib can double the years left to live for patients with pancreatic cancer, but it does not cure the disease and is only effective if treatment begins early.

A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib showed durable responses in most pancreatic cancer patients in an early-stage trial. Revolution's drug has demonstrated unprecedented outcomes, highlighting potential in oncology treatments.

The article discusses how certain 'healthy' oils commonly used in cooking may contribute to pancreatic cancer and identifies foods that offer protection against the disease.

The article highlights a link between the drug Mounjaro and pancreatic cancer, noting that three-quarters of patients die within a year as cases rise. It also mentions a landmark study examining the impact of 'fat jabs' against the disease.

A landmark study reveals a link between Mounjaro and pancreatic cancer, noting that three-quarters of patients die within a year. Cases of the disease are rising, and the study examines the impact of 'fat jabs' on pancreatic cancer.

A new daily pill for pancreatic cancer has shown to reduce the risk of death by 60% compared to chemotherapy in a study involving 500 patients. The drug, developed by a biotech company, is doubling survival time for patients with an aggressive form of the disease.

Recent breakthroughs in medicine, including Revolution Medicines' pancreatic cancer treatment and Eli Lilly's anti-obesity drug, show significant progress in extending patient survival and reducing body weight. These advancements stem from decades of research investment but face challenges like high costs and the need for long-term use.

Revolution Medicines' pancreatic cancer drug, daraxonrasib, received a standing ovation from oncologists during a data presentation. The article also addresses the poor performance of biotech stocks this week and discusses other topics on 'The Readout LOUD' podcast.

A new pill doubling survival time for pancreatic cancer and major advancements in breast, bladder, and neck cancer treatments were announced at the American Society of Clinical Oncology conference in Chicago, sparking widespread medical community acclaim.

Amy Johnston, a pancreatic cancer patient, is participating in a clinical trial for daraxonrasib, a drug that nearly doubled survival time in trials. Revolution Medicines is offering the drug via an expanded access program, but patients face anxiety over supply shortages and prioritization.

Scientists have developed a drug, daraxonrasib, targeting the KRAS mutation in pancreatic cancer, which was previously considered undruggable. The drug nearly doubled survival rates for patients with advanced pancreatic cancer and reduced the risk of death by 60% in a major clinical trial.

A Redwood City company, Revolution Medicines, developed an experimental pill called daraxonrasib for pancreatic cancer, showing trial results that doubled patient survival rates from six and a half months to over 13 months compared to chemotherapy. The drug is now being fast-tracked by the FDA.

A landmark treatment for pancreatic cancer has shown unprecedented results, offering hope for targeting other challenging tumors. The breakthrough highlights optimism for addressing previously difficult-to-treat cancers.

The article highlights a surge in pancreatic cancer cases among women under 55, urging readers to eliminate a specific daily habit and recognize an early warning signal to improve survival chances. Dr. Max Pemberton is cited as the source of these recommendations.

Ben Sasse discusses his stage-four pancreatic cancer diagnosis, emphasizes family roots in Nebraska, and shares parenting strategies focused on service and gratitude. He reflects on political and technological changes impacting American life.

Dr. Thomas Pudlarz, a Medical Oncologist at the Gustave-Roussy Institute, highlights a new experimental targeted therapy for pancreatic cancer as a significant advancement. Pancreatic cancer remains a major challenge in oncology, but this therapy represents one of the first improvements in many years.

A study found that oleic acid, found in olive oil, accelerated pancreatic cancer growth in mice, while omega-3-rich fats from fish oil significantly slowed the disease. The research highlights that the type of fat consumed may be more critical than the quantity in pancreatic cancer development.

An experimental drug for pancreatic cancer, taken once daily, has shown promising results in slowing cancer progression and extending patient survival. Dr. Rachna Shroff from the University of Arizona Comprehensive Cancer Center discusses the treatment's potential.

A new drug in trials demonstrated that pancreatic cancer patients survived twice as long as those treated with chemotherapy alone. Dr. Jon LaPook reported on the findings.

The ASCO meeting highlighted discussions on barriers to cancer care and new treatments, including Brian Wolpin's presentation on the daraxonrasib pancreatic cancer study, which received a sustained standing ovation. The article concludes with a farewell from Chicago and an invitation to a virtual recap.

An experimental drug that doubles survival time for pancreatic cancer is being hailed as a breakthrough for combating one of the world's deadliest cancers.

An experimental daily pill for advanced pancreatic cancer nearly doubled survival time compared to chemotherapy infusions. Patients taking the drug lived significantly longer than those receiving traditional treatment.

A new drug nearly doubles survival rates for some pancreatic cancer patients, according to a study. Dr. Harsh Singh from the MGB Cancer Institute provided additional details.

A new drug for pancreatic cancer is offering patients hope for survival against a deadly form of cancer. Dr. Jon LaPook reports more details.

Revolution Medicines' pancreatic cancer drug daraxonrasib showed a 60% reduction in mortality risk compared to chemotherapy, with a median survival of 13.2 months. China's biotechnology sector is rapidly growing, marked by a first-ever China-only clinical trial presentation at the ASCO conference.